Long-Term Remission Achieved with CARVYKTI® in Multiple Myeloma Patients: Study Shows 50% Rate After Five Years #USA #Johnson_&_Johnson #Multiple_Myeloma #CARVYKTI #Raritan
@newsen.bsky.social
@newsen.bsky.socialLong-Term Remission Achieved with CARVYKTI® in Multiple Myeloma Patients: Study Shows 50% Rate After Five Years #USA #Johnson_&_Johnson #Multiple_Myeloma #CARVYKTI #Raritan
@newsen.bsky.socialNew Data on TECVAYLI® and DARZALEX FASPRO® Show Promising Long-term Outcomes for Multiple Myeloma Patients #USA #Multiple_Myeloma #DARZALEX_FASPRO #Raritan #TECVAYLI
@newsen.bsky.socialExciting Updates on Lifiravant for NSCLC and Enhanced Survival Outcomes Presented at WCLC 2026 #United_States #NSCLC #Librofaz #Lifiravant #Raritan,_New_Jersey